Short answer
MANNKIND CORP (MNKD) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 8.01 (Other Events). FDA expanded Afrezza approval to children and adolescents aged 6 and older with type 1 or type 2 diabetes.
MANNKIND CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA expanded Afrezza approval to children and adolescents aged 6 and older with type 1 or type 2 diabetes
- Pediatric label expansion opens access to a population exceeding 350,000 U.S. children and adolescents with diabetes
- FDA confirmed Afrezza’s supplemental application fulfilled the final postmarketing requirement from its June 27, 2014 approval
- Broader labeling may support Afrezza adoption and commercial growth across pediatric insulin therapy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MANNKIND CORP 8-K filings
Get the next MNKD 8-K as it lands
Follow MNKD for push alerts, or ask the research agent what this filing means.